LR-MDS with Transfusion-Dependent Anemia – ESA Refractory, RS+ : Episode 3

Mechanism of Action: Imetelstat in LR MDS

August 14, 2024

By Abdulraheem Yacoub, MD

Opinion

Video

EP: 1.ESA-Ineligible LR MDS patient with Transfusion-Dependent Anemia

EP: 2.Therapy Selection for ESA Ineligible LR-MDS Patients

Now Viewing

EP: 3.Mechanism of Action: Imetelstat in LR MDS

EP: 4.Efficacy and Safety of Imetelstat in ESA- ineligible patients

EP: 5.Adverse Event Profile & Management of Imetelstat

EP: 6.Comparing Telomerase Inhibitors and EMAs in ESA-Ineligible LR MDS

EP: 7.74- year-old man with LRMDS and Transfusion Dependent Anemia

EP: 8.Efficacy and Safety of 2L therapies for RS+ patients

EP: 9.EMA vs Telomerase Inhibitor for RS+ patients after ESA failure

EP: 10.Optimizing Anemia Management and Addressing Unmet Needs in LR MDS

Please discuss the mechanism of action for imetelstat, a first-in-class oligonucleotide telomerase inhibitor in LR-MDS.

Related Content

Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment

Jordyn Sava

March 16th 2025

Article

The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test.

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Nichole Tucker

June 30th 2023

Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen

First Patient Dosed in Phase 1/2 Trial of HLD-0915 for mCRPC

Jordyn Sava

March 5th 2025

Article

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to 80 patients.

First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

Jordyn Sava

March 3rd 2025

Article

A global, randomized, phase 1b/2 trial is evaluating IO-108 in patients with metastatic and/or unresectable hepatocellular carcinoma.

First Patient Dosed in IB-T101 ccRCC Trial

Jordyn Sava

February 27th 2025

Article

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma treatment in a dose-escalation trial.

First Patient Dosed in Study of Iadademstat Combo in MDS

Jordyn Sava

February 26th 2025

Article

The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical College of Wisconsin.

Related Content

Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment

Jordyn Sava

March 16th 2025

Article

The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test.

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Nichole Tucker

June 30th 2023

Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen

First Patient Dosed in Phase 1/2 Trial of HLD-0915 for mCRPC

Jordyn Sava

March 5th 2025

Article

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to 80 patients.

First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

Jordyn Sava

March 3rd 2025

Article

A global, randomized, phase 1b/2 trial is evaluating IO-108 in patients with metastatic and/or unresectable hepatocellular carcinoma.

First Patient Dosed in IB-T101 ccRCC Trial

Jordyn Sava

February 27th 2025

Article

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma treatment in a dose-escalation trial.

First Patient Dosed in Study of Iadademstat Combo in MDS

Jordyn Sava

February 26th 2025

Article

The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical College of Wisconsin.

Do Not Sell My Information